Compare EMR & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMR | GSK |
|---|---|---|
| Founded | 1890 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6B | 96.1B |
| IPO Year | 1994 | N/A |
| Metric | EMR | GSK |
|---|---|---|
| Price | $148.62 | $59.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $157.85 | N/A |
| AVG Volume (30 Days) | 4.2M | ★ 6.3M |
| Earning Date | 05-02-2026 | 01-01-0001 |
| Dividend Yield | 1.47% | ★ 2.95% |
| EPS Growth | ★ 17.78 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $24,412,000,000.00 | N/A |
| Revenue This Year | $6.26 | $6.75 |
| Revenue Next Year | $5.36 | $4.88 |
| P/E Ratio | $138.90 | ★ $32.75 |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $90.06 | $32.38 |
| 52 Week High | $165.15 | $61.70 |
| Indicator | EMR | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 70.79 |
| Support Level | $144.10 | $58.02 |
| Resistance Level | $153.42 | $61.70 |
| Average True Range (ATR) | 5.29 | 0.96 |
| MACD | -0.81 | 0.26 |
| Stochastic Oscillator | 37.15 | 82.17 |
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.